Presidential Symposium

• 

  PS Current Role and Future Direction of Hematopoietic Cell Transplantation Mary Horowitz Medical College of Wisconsin, USA CV

Plenary Session 1: State of the Art in Cell Therapy

• 

  PL01 T-cell Therapies for Blood Cancers Catherine Bollard George Washington University, USA CV
• 

  PL01 Multi-targeted CAR-T Therapy – Overcoming CD19 Antigen Loss David B. Miklos Stanford University, USA CV

Plenary Session 2: How to Treat Steroid-Refractory Graft vs. Host disease

• 

  PL02 Treatment for Steroid-Refractory Acute GVHD Paul J. Martin Fred Hutchinson Cancer Center, USA CV
• 

  PL02 Treatment for Steroid-Refractory Chronic GVHD Takanori Teshima Hokkaido University Hospital, Japan CV

Scientific Session 1: Strategies to Prevent Leukemia Relapse after HSCT

• 

  SS01-1 Maintenance Therapy in AML to Prevent Relapse after Allogeneic HSCT Uwe Platzbecker Leipzig University Hospital, Germany CV
• 

  SS01-2 Management of Acute Leukemias Relapsing after the First Allogeneic HCT: A Second Allogeneic HCT or DLI? Mohamed A. Kharfan-Dabaja Mayo Clinic, USA CV
• 

  SS01-3 Relapse Prevention after Allogeneic HSCT in Adult ALL Nicola Gökbuget Goethe University, Germany CV

Scientific Session 2: Donor Selection and Engraftment in HSCT

• 

  SS02-1 What to Consider in Donor Selection with Alternative Donors? Rupert Handgretinger Eberhard Karls University Tuebingen, Germany CV
• 

  SS02-2 Primary Graft Failure in Pediatric Non-Malignant Disease: An Old but Critical Hurdle Troy Lund University of Minnesota, USA CV
• 

  SS02-3 New Insights of Overcoming Poor Graft Function after Allogeneic HSCT in Hematologic Malignancies Rajat Kumar Princess Margaret Cancer Center, Canada CV

Scientific Session 3: Recent Advances in Transplant Immunology & Genomics

• 

  SS03-1 Suppressive Role of Bone Marrow-Derived IDO1 in Graft-Versus-Host Disease Eun Young Choi Seoul National University College of Medicine, Korea CV
• 

  SS03-2 The Role of the Intestinal Microbiome in Cancer Immunotherapy Marcel van den Brink Memorial Sloan Kettering Cancer Center, USA CV
• 

  SS03-3 Genomics in HSCT: Improving Transplant Outcomes Myungshin Kim The Catholic University of Korea, Korea CV

Scientific Session 4: Hematopoietic Stem Cell Transplantation in Lymphoid Malignancy

• 

  SS04-1 Redefining the Role of Transplant for Patients with T-cell Lymphoma in the Immunotherapy Era Satoshi Yamasaki National Hospital Organization Kyushu Medical Center, Japan CV
• 

  SS04-2 Updates of Consolidation and Maintenance Strategies in Primary CNS Lymphoma Tracy T Batchelor Massachusetts General Hospital Cancer Center, USA CV
• 

  SS04-3 The Future Directions of Maintenance with or without Consolidation Therapy in Myeloma Philip L. McCarthy Roswell Park Cancer Institute, USA CV
• 

  SS04-4 Circulating miRNAs as Prognostic Biomarkers in Multiple Myeloma Patients Undergoing Transplant Sung-Soo Park The Catholic University of Korea, Korea CV

Scientific Session 5: Database & Artificial Intelligence in Hematologic Malignancies

• 

  SS05-1 Optimal Donor Selection Algorithm Based on CIBMTR Data Bronwen Shaw Medical College of Wisconsin, USA CV
• 

  SS05-2 Who to Transplant in CR1? Integrating Knowledge-Bank Approaches in Daily Practice Raphael Itzykson Hopital Saint-Louis, France CV
• 

  SS05-3 St. Jude Cloud: A Genomic Data-Sharing Ecosystem for Advancing Research & Treatment in Pediatric Cancer & Blood Diseases Jinghui Zhang St. Jude Children’s Research Hospital, USA CV

Scientific Session 6: Recent Advances in Cellular Immunotherapy

• 

  SS06-1 Next Generation CAR-T Cell Therapy in Multiple Myeloma Sham Mailankody Memorial Sloan Kettering Cancer Center, USA CV
• 

  SS06-2 Clinical Application of Innovative Cellular Immunotherapy for Cancer Je-Jung Lee Chonnam National University Medical School, Korea CV
• 

  SS06-3 Infusion of Donor Memory-like NK Cells and Post-Transplant Relapse Rizwan Romee Harvard Medical School, USA CV

Scientific Session 7: New Insights of Microbiome in HSCT

• 

  SS07-1 Insights into the Role of Gut Microbiota in HSCT: GVHD and Infection Daniele Zama University of Bologna, Italy CV
• 

  SS07-2 Manipulation of Microbiome in HSCT Edoardo Muratore University of Bologna, Italy CV
• 

  SS07-3 The potential Role of Gut Microbiome in the Immunobiology of CAR-T Cell Therapy Christoph K. Stein-Thoeringer Deutsches Krebsforschungszentrum, Germay CV

Scientific Session 8: Current Status and Perspective of GVHD Management

• 

  SS08-1 Risk Stratification of GVHD with Clinical Prediction System and Novel Biomarkers John E. Levine The Tisch Cancer Institute, Mount Sinai School of Medicine, USA CV
• 

  SS08-2 Updated Strategies of GVHD Prevention Ho Sup Lee Kosin University College of Medicine, Korea CV
• 

  SS08-3 Biology Based Novel Treatment Approaches of GVHD Tomomi Toubai Yamagata University, Japan CV

Scientific Session 9: Challenges in Allogeneic Transplantation for MDS

• 

  SS09-1 The Transplant Decision, before and after: When and Who Should Be Considered and How Should be prepared Jae-Sook Ahn Chonnam National University College of Medicine, Korea CV
• 

  SS09-2 The Dilemma of Optimal Conditioning Strategy in MDS: The Stronger, the Better? Sebastian Giebel Maria Sklodowska-Curie Cancer Center, Poland CV
• 

  SS09-3 Impact of MDS Genomics on Post-Transplant Relapse Bhagirathbhai Dholaria Vanderbilt University Medical Center, USA CV

Scientific Session 10: Transplantation of Pediatric Leukemia

• 

  SS10-1 The Role of HSCT With Pediatric ALL Patients in the Immunotherapy Era Mattia Algeri Bambino Gesù Childrens’ Hospital, Italy CV
• 

  SS10-2 Optimal Conditioning Therapy in Childhood ALL: Total Body Irradiation vs. Chemotherapy-Based Conditioning Seungmin Hahn Yonsei University College of Medicine, Korea CV
• 

  SS10-3 Who Should Be Considered to Receive HSCT in Pediatric CML? Nobuko Hijiya Columbia University Medical Center, USA CV

Scientific Session 11: Understanding of Bone Marrow Niche

• 

  SS11-1 Illuminating Functional Heterogeneity of the Bone Marrow Microenvironment Anastasia N. Tikhonova University of Toronto, Canada CV
• 

  SS11-2 Immunologic Changes and T-cell Receptor (TCR) Repertoire in Aplastic Anemia and Related Bone Marrow Failure Diseases Satu Mustjoki University of Helsinki, Finland CV
• 

  SS11-3 Proteomic Analysis of Acute Myeloid Leukemia-Derived Extracellular Vesicles Kwang Pyo Kim Department of Applied Chemistry, Kyung Hee University, Korea CV

Scientific Session 12: Advanced Cell Therapy Using Cord Blood

• 

  SS12-1 Hematopoietic Stem Cell Transplantation Using Single UM171-Expanded Cord Blood: A Single-Arm, Phase 1-2 Safety and Feasibility Study Sandra Cohen University of Montreal, Canada CV
• 

  SS12-2 Reduced-Intensity Single-Unit Unrelated Cord Blood Transplant with Optional Immune Boost for Nonmalignant Disorders Paul Szabolcs University of Pittsburgh School of Medicine, USA CV
• 

  SS12-3 Cell Expansion Using Cord Blood Cells - Generation of NK Cells with Cord Blood Cells Yu-Kyeong Hwang YUYA Bio Consulting, Korea CV

Joint Symposium 1: JSTCT-KSBMT: Unmet Needs of Alternative Donor Transplantation in SAA

• 

  JS01-1 TBI-Containing Conditioning Regimens without ATG in Adults with Aplastic Anemia Undergoing CBT Nobuhiro Hiramoto Kobe City Medical Center General Hospital, Japan CV
• 

  JS01-2 Alternative Donor HSCT for SAA in Korea Jae Wook Lee The Catholic University of Korea, Korea CV
• 

  JS01-3 Investigation of Telomere Length Shortening in Pediatric Aplastic Anemia and Congenital Bone Marrow Failure Atsushi Narita Nagoya University, Japan CV
• 

  JS01-4 Comparison of HSCT and TPO-RAs with IST in SAA Jun Ho Jang Sungkyunkwan University School of Medicine, Korea CV

Joint Symposium 2: EBMT-KSBMT: Recent Advances in Haploidentical HCT

• 

  JS02-1 New Strategies of Unmanipulated Haploidentical Cell Transplantation Annalisa Ruggeri IRCCS San Raffaele Scientific Institute, Italy CV
• 

  JS02-2 Haplo-HCT vs. Other Sources Alberto Mussetti Catalan Institute of Oncology, Spain CV
• 

  JS02-3 Graft Manipulation Strategies for Haploidentical Hematopoietic Cell Transplantation Ho Joon Im University of Ulsan College of Medicine, Korea CV
• 

  JS02-4 Haploidentical Transplantation in Myeloid Maliagnancy: Is It a Just Alternative Option? Silvia Park The Catholic University of Korea, Korea CV

Joint Symposium 3: ASTCT-KSBMT: Clonal Hematopoiesis and HCT/Cellular therapy

• 

  JS03-1 Clonal Hematopoiesis in Donors for Allogeneic Hematopoietic Stem Cell Amy Dezern Johns Hopkins University, USA CV
• 

  JS03-2 Pathobiology of Clonal Hematopoiesis and Hematologic Diseases Youngil Koh Seoul National University College of Medicine, Korea CV
• 

  JS03-3 Clonal Hematopoiesis and Its Effects on Cellular Therapies (CAR T-Cell Therapy Outcomes) Kelly Bolton Washington University School of Medicine in St. Louis, USA CV

Joint Symposium 4: ISCT-KSBMT: Gene Editing and Gene Therapy

• 

  JS04-1 Gene Editing for Treatment of Hematological Disorders Alok Srivastava Christian Medical College, India CV
• 

  JS04-2 Towards Next Generation T Cell Engineering for Cancer Immunotherapy Chan Hyuk Kim KAIST, Korea CV
• 

  JS04-3 Enhanced Anti-Tumor Effects of Glioblastoma-Targeting CAR-T Cells by CRISPR-Cas9 Jung Min Lee Handong University School of Life Science, Korea CV

Joint Symposium 5: TSBMT-KSBMT: Allogeneic HCT for HLH

• 

  JS05-1 HSCT for HLH or Other Histiocytic Disorders Sule Unal Hacettepe University, Türkiye CV
• 

  JS05-2 Recent Progress in Hematopoietic Cell Transplantation for Pediatric Patients with Hemophagocytic Lymphohistiocytosis Jin Kyung Suh Korea Cancer Center Hospital, Korea CV

East Asia Collaborative Session: Current Status of CAR-T Cell Therapy in East Asia

• 

  EACS-1 Current Status of CAR-T Cell Therapy in Taiwan Bor-Sheng Ko National Taiwan University Cancer Center, Taiwan CV
• 

  EACS-2 Development of CAR-T in China Xiao jun Huang Peking University Institute of Hematology, China CV
• 

  EACS-3 CAR T-Cell Therapy in Korea : Clinical Trials and Practice Seok Jin Kim Sungkyunkwan University School of Medicine, Korea CV

Education Session 1: What Should We Know to Reduce Transplant-Related Mortality

• 

  ES01-1 Diagnosis and Management of Vascular Endothelial Syndrome after HSCT Thomas Luft University of Heidelberg, Germany CV
• 

  ES01-2 Optimal Administration of Antifungal Agents during Transplantation Malgorzata Mikulska University of Genova, Italy CV
• 

  ES01-3 Updates of Prophylaxis and Treatment with Viral Infections in Transplant Setting Young Kyung Yoon Korea University College of Medicine, Korea CV

Education Session 2: Practical Problems Related with CAR-T Cell Therapy

• 

  ES02-1 Recognizing and Managing CRS and ICANS: Emerging Roles of Alternative Agents Daniel W. Lee University of Virginia, USA CV
• 

  ES02-2 Importance of Fludarabine Pharmacokinetics Kevin J Curran Memorial Sloan Kettering Cancer Center, USA CV
• 

  ES02-3 Practical Considerations for Preparing CAR-T Cell Therapy Hee Young Ju Sungkyunkwan University School of Medicine, Korea CV

Education Session 3: Survivorship after HSCT: Focusing on Rare Complications

• 

  ES03-1 Cardiovascular Health after Hematopoietic Cell Transplantation Melissa Hudson St. Jude Children's Research Hospital, USA CV
• 

  ES03-2 Bone Health in Hematologic Stem Cell Transplant Recipients David Kendler University of British Columbia, Canada CV
• 

  ES03-3 Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation K Scott Baker Fred Hutchinson Cancer Research Center, USA CV

Education Session 4: Allogeneic HSCT in Non-Malignant Diseases

• 

  ES04-1 Special Strategies of Allogeneic Transplantation in Primary Immune Deficiencies Sung-Yun Pai National Cancer Institute, USA CV
• 

  ES04-2 Allogeneic HSCT in Thalassemia in the Era of Gene Therapy Sandeep Soni Stanford University, USA CV
• 

  ES04-3 Haploidentical Transplant and Other Novel Non-Transplant Modalities in Genetic Diseases Suradej Hongeng Ramathibodi Hospital, Thailand CV

Education Session 5: Supportive Care with HSCT

• 

  ES05-1 COVID Recommendations Updates in Transplant Patients Sung-Han Kim University of Ulsan College of Medicine, Korea CV
• 

  ES05-2 Palliative and Advanced Care Planning: End of Life Issues Areej El-Jawahri Massachusetts General Hospital, Harvard Medical School, USA CV
• 

  ES05-3 Cognitive Function in Blood/Marrow Transplant Survivors Smita Bhatia University of Alabama at Birmingham, USA CV

Education Session 6: Optimal Strategies for HSCT with Elderly Patients

• 

  ES06-1 Geriatric Assessment to Select Optimal Candidates for HSCT Gi June Min The Catholic University of Korea, Korea CV
• 

  ES06-2 Appropriate Conditioning Regimens in Elderly Patients for HSCT Joon Ho Moon Kyungpook National University Hospital, Korea CV
• 

  ES06-3 Donor sources for Older Transplant Recipients and Graft vs. Host Disease Melhem Solh Blood and Marrow Transplant Program at Northside Hospital, USA CV

Debate Session 1: Posttransplant Cyclophosphamide vs. Antithymocyte Globulin

• 

  DS01-1 Debates in GVHD Prophylaxis - PTCY versus ATG: From the PTCY Perspective Ji Hyun Lee Dong-A University College of Medicine, Korea CV
• 

  DS01-2 Debates in GVHD Prophylaxis- PTCy versus ATG. From the ATG Perspective Dong-Yeop Shin Seoul National University College of Medicine, Korea CV

Debate Session 2: TBI vs. non-TBI for ALL Treatment

• 

  DS02-1 TBI Sung Han Kang University of Ulsan College of Medicine, Korea CV
• 

  DS02-2 non-TBI Kyung Taek Hong Seoul National University College of Medicine, Korea CV

Nursing Session 1: Special Nursing Field of Hemato-Oncology nurses

• 

  NS01-1 Palliative and Hospice Care for Children, Adolescents with Hematologic Malignancies Sun Hee Choi The Catholic University of Korea, Korea CV
• 

  NS01-2 Nursing Strategies on CAR-T Cell Therapy Yujeong Kim Samsung Medical Center, Korea CV

Nursing Session 2: New Therapy of Hematologic Malignancies and Infection

• 

  NS02-1 Updates of Therapeutic Stategies in Hematologic Malignancies Ja Min Byun Seoul National University College of Medicine, Korea CV
• 

  NS02-2 Updates in Management of Infectious Diseases in Hematology Patients Sung-Yeon Cho The Catholic University of Korea, Korea CV

Luncheon Symposium 1: Kyowa Kirin Korea

• 

  LS01 Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma Tatsu Shimoyama Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan CV

Luncheon Symposium 2: Janssen Korea

• 

  LS02 Treatment of Newly Diagnosed Transplant Eligible Myeloma : What is the Optimal Induction? Mario Boccadoro University of Turin, Italy CV

Luncheon Symposium 3: Novartis Korea

• 

  LS03 How to Treat Steroid Refractory GvHD Optimally with Ruxolitinib Robert Zeiser University Medical Center Freiburg, Germay CV

Luncheon Symposium 4: Astellas Pharma Korea

• 

  LS04 Optimizing the Management of FLT3 mt R/R AML in Older and Frail Patient Eunice Wang Roswell Park Comprehensive Cancer Center, USA CV

Luncheon Symposium 5: Sanofi-aventis Korea

• 

  LS05 The Role of ATG in GVHD Prophylaxis: Where do we stand? Dennis Kim Princess Margaret Cancer Centre, University of Toronto, Canada CV

Luncheon Symposium 6: Bristol Myers Squibb (BMS)

• 

  LS06 Oral Azacitidine Maintenance Therapy after Intensive Chemotherapy for Transplant-Ineligible AML Patients Andrew Wei Monash University, Australia CV

Luncheon Symposium 7: Handok Inc.

• 

  LS07 Current Perspectives of Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation; Recent Defitelio Data and Introducing Korean Data Jae-Ho Yoon The Catholic University of Korea, Korea CV

Luncheon Symposium 8: MSD KOREA

• 

  LS08 Paradigm Change of CMV Prophylaxis-Letermovir Dong-Yeop Shin Seoul National University College of Medicine, Korea CV